bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
HEPCPCR

Order Name:
PCR for HCV (Qualitative Method)

 
Useful For:
Use for detection of acute hepatitis C virus (HCV) infection and confirmation of chronic HCV infection.
 
Methodology:
Real Time Polymerase chain reaction (Real-Time PCR)
 
AliasesName:
HCV RNA qualitative
Hepatitis C virus detection by PCR
HCV by PCR
PCR for Hepatitis C virus (HCV)
 
 
 
Test Code:
HEPCPCR

Order Name:
PCR for HCV (Qualitative Method)

 
Collection Specimen Or Container:
Blood/ Plain blood (Red top) 6 mL, 1 tube
 
Specimen Testing Type:
Serum, minimum volume 1 mL 
Separate plasma within 24 hours of collection.
 
Sub Mission Container:
Plastic tube
 
Rejection Criteria:
Hemolysis: N/A
Lipemia: N/A
Icterus: N/A
Other: Heparin, anticoagulant blood
 
Specimen Stabillity:
Specimen Type Temperature Time
Whole blood At temperature, 2oC to 25oC 24 hours
Serum Refrigerated, 2oC to 8oC 72 hours
Frozen, -20oC to -80oC 6 weeks.
 
 
 
Test Code:
HEPCPCR

Order Name:
PCR for HCV (Qualitative Method)

 
Method detail:
Real Time Polymerase chain reaction (Real-Time PCR)
 
Schedule:
Monday through Saturday, at 1:00 p.m.and 07:00 p.m.
 
Turnaround Time:
Received specimen to reported within 2 days.
 
Performing Location:
Molecular biology & Genetics, Laboratory Department Tel.14168
 
Specimen Retention Time:
2 months
 
 
 
Test Code:
HEPCPCR

Order Name:
PCR for HCV (Qualitative Method)

 
 
Clinical Information:
Hepatitis C Virus is considered to be the principal etiologic agent responsible for 90 to 95% of the cases of post-transfusion hepatitis. As a blood-borne virus, HCV can be transmitted by blood and blood products. The incidence of HCV infection is highest in association with intravenous drug abuse and to a lesser extent with other percutaneous exposures. Spontaneous viral clearance rates in exposed individuals are highly variable; between 10 and 60% have been reported as measured clinically by normalization of liver enzymes and clearance of plasma HCV RNA. HCV virus particles cannot be cultured from infected blood samples; hence the presence of anti-HCV antibodies in patients infected with HCV has led to the development of immunoserological assays that are specific for these antibodies. The presence of anti-HCV antibodies, however, is a measure of prior exposure to HCV infection, but cannot be considered a marker for current infection. Furthermore, in cases of acute HCV infection, individuals may fail to produce antibody to HCV, making diagnosis of current HCV infection impossible using immunoserological techniques. Alternatively, detection of HCV RNA by nucleic acid tests may provide evidence for current infection. Using nucleic acid tests, it is possible to detect HCV viremia prior to immunological sero-conversion.
 
Reference Value:
Negative
 
Interpretation:
  1. A result of "Negative" indicates the absence of HCV RNA in the patient's serum.
  2. Reliable results are dependent on adequate specimen collection, transport, storage and processing procedures.
  3. Mutations within the highly conserved regions of the viral genome covered by the test primers and/or probes have been identified and may result in under-quantitation of or failure to detect the virus.
  4. Detection of HCV RNA is dependent on the number of virus particles present in the specimen and may be affected by specimen collection methods and patient factors, (ie, age, presence of symptoms, and/or stage of the infection).
 
Clinical Reference:
Manufacturer’s package insert, COBAS®AmpliPrep/COBAS® TaqMan® HCV Quantitative Test, version 2.0, September 2019, Roche Molecular Systems, NJ 08876 Branchburg, USA.